PURPOSE: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a matrix-bound inhibitor of matrix metalloproteinases (MMPs). The authors have previously determined a novel function of TIMP-3 to inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis. Here, the authors examined the in vivo angiogenic phenotype of ocular vessels in mice deficient in TIMP-3. METHODS: VEGF-mediated corneal neovascularization and laser-induced choroidal neovascularization (CNV) were examined in TIMP-3-null mice. The effects of the absence of TIMP-3 on the phosphorylation status of the VEGF-receptor-2 (VEGFR-2) and the downstream signaling pathways were evaluated biochemically. In addition, the activation state of MMPs in the retina of TIMP-3-deficient mice was examined by in situ zymography. RESULTS: The results of these studies determine an accentuation of pathologic VEGF-mediated angiogenesis in the cornea and laser-induced CNV in mice lacking TIMP-3. In the absence of the MMP inhibitor, pathophysiological changes were observed in the choroidal vasculature concomitantly with an increase in gelatinolytic activity. These results suggest that an imbalance of extracellular matrix homeostasis, together with a loss of an angiogenesis inhibitor, can prime vascular beds to be more responsive to an angiogenic stimulus. CONCLUSIONS: In light of the recent studies suggesting that genetic variants near TIMP-3 influence susceptibility to age-related macular degeneration, these results imply that TIMP-3 may regulate the development of the choroidal vasculature and is a likely contributor to increased susceptibility to choroidal neovascularization.
PURPOSE:Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a matrix-bound inhibitor of matrix metalloproteinases (MMPs). The authors have previously determined a novel function of TIMP-3 to inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis. Here, the authors examined the in vivo angiogenic phenotype of ocular vessels in mice deficient in TIMP-3. METHODS:VEGF-mediated corneal neovascularization and laser-induced choroidal neovascularization (CNV) were examined in TIMP-3-null mice. The effects of the absence of TIMP-3 on the phosphorylation status of the VEGF-receptor-2 (VEGFR-2) and the downstream signaling pathways were evaluated biochemically. In addition, the activation state of MMPs in the retina of TIMP-3-deficient mice was examined by in situ zymography. RESULTS: The results of these studies determine an accentuation of pathologic VEGF-mediated angiogenesis in the cornea and laser-induced CNV in mice lacking TIMP-3. In the absence of the MMP inhibitor, pathophysiological changes were observed in the choroidal vasculature concomitantly with an increase in gelatinolytic activity. These results suggest that an imbalance of extracellular matrix homeostasis, together with a loss of an angiogenesis inhibitor, can prime vascular beds to be more responsive to an angiogenic stimulus. CONCLUSIONS: In light of the recent studies suggesting that genetic variants near TIMP-3 influence susceptibility to age-related macular degeneration, these results imply that TIMP-3 may regulate the development of the choroidal vasculature and is a likely contributor to increased susceptibility to choroidal neovascularization.
Authors: C Schwesinger; C Yee; R M Rohan; A M Joussen; A Fernandez; T N Meyer; V Poulaki; J J Ma; T M Redmond; S Liu; A P Adamis; R J D'Amato Journal: Am J Pathol Date: 2001-03 Impact factor: 4.307
Authors: Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen Journal: Am J Pathol Date: 2005-11 Impact factor: 4.307
Authors: Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Andreas Janssen; Julia Hoellenriegel; Marton Fogarasi; Heinrich Schrewe; Mathias Seeliger; Ernst Tamm; Andreas Ohlmann; Christian Albrecht May; Bernhard H F Weber; Heidi Stöhr Journal: Invest Ophthalmol Vis Sci Date: 2008-04-11 Impact factor: 4.799
Authors: A Amour; P M Slocombe; A Webster; M Butler; C G Knight; B J Smith; P E Stephens; C Shelley; M Hutton; V Knäuper; A J Docherty; G Murphy Journal: FEBS Lett Date: 1998-09-11 Impact factor: 4.124
Authors: Nina Jasmin Hewing; Gisela Weskamp; Joost Vermaat; Eric Farage; Krzysztof Glomski; Steven Swendeman; Robison Vernon Paul Chan; Michael F Chiang; Rama Khokha; Bela Anand-Apte; Carl Peter Blobel Journal: Invest Ophthalmol Vis Sci Date: 2013-01-30 Impact factor: 4.799
Authors: Yantenew G Gete; Luke W Koblan; Xiaojing Mao; Mason Trappio; Bhushan Mahadik; John P Fisher; David R Liu; Kan Cao Journal: Aging Cell Date: 2021-06-04 Impact factor: 9.304
Authors: Yung-Yi Chen; Nicola J Brown; Rita Jones; Claire E Lewis; Ahmed H Mujamammi; Munitta Muthana; Michael P Seed; Michael D Barker Journal: Angiogenesis Date: 2013-10-16 Impact factor: 9.596
Authors: Jian Hua Qi; Quteba Ebrahem; Mariya Ali; Alecia Cutler; Brent Bell; Nicholas Prayson; Jonathan Sears; Vera Knauper; Gillian Murphy; Bela Anand-Apte Journal: PLoS One Date: 2013-03-01 Impact factor: 3.240